In a large, clinically representative breast cancer cohort, we examined the prevalence and characteristics of BRCA1/2 germline mutation carriers and compared our results with BRCA mutation carriers already identified through a national clinical BRCA screening program. This evidence concerns the gene BRCA1 and breast carcinoma.